Remove Art Remove Confidentiality Remove Ownership Remove Public Use
article thumbnail

The IPKat EPO Boards of Appeal Year in Review 2023

The IPKat

The topic of prior use has been elevated to the status of a referral to the Enlarged Board of Appeal ( G1/23 ). The free evaluation of evidence of prior use (T 0042/19) New EBA referral: When is prior use of a product excluded from the prior art for lack of enablement? This is one to watch for 2024.

Invention 110
article thumbnail

Biosimilars 2020 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

The parties are currently engaged in supplemental expert discovery on Hospira and Pfizer’s on-sale bar and public use defenses, and the court has resolved two discovery disputes this year stemming from these issues. Non-Confidential Brief for Plaintiff-Appellant at 25, 35.) 9,643,997, which is directed to protein purification.